

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/127		A1	(11) International Publication Number: WO 98/58630 (43) International Publication Date: 30 December 1998 (30.12.98)
(21) International Application Number:	PCT/US98/12937		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	22 June 1998 (22.06.98)		
(30) Priority Data:	60/050,490	23 June 1997 (23.06.97)	US
(71) Applicant:	SEQUUS PHARMACEUTICALS, INC. [US/US]; 960 Hamilton Court, Menlo Park, CA 94025 (US).		
(72) Inventors:	ALLEN, Theresa, M.; 11223 72nd Street, Edmonton, Alberta T6G 0B4 (CA). STUART, Darrin; 191 Michener Park, Edmonton, Alberta T6H 4M4 (CA).		Published <i>With international search report.</i>
(74) Agents:	MOHR, Judy, M. et al.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).		

(54) Title: LIPOSOME-ENTRAPPED POLYNUCLEOTIDE COMPOSITION AND METHOD

(57) Abstract

A liposome composition for administration of a polynucleotide and a method of preparation of the composition are described. The liposomes in the suspension are composed predominantly of liposomes having a bilayer membrane formed of cationic vesicle-forming lipids and neutral vesicle-forming lipids. The polynucleotide is entrapped in the central core of the liposomes and is localized predominantly on the inner surface of the core.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

LIPOSOME-ENTRAPPED POLYNUCLEOTIDE
COMPOSITION AND METHOD

5 This application claims the priority of U.S. provisional application no. 60/050,490, filed June
23, 1997, which is incorporated herein by reference.

Field of the Invention

The present invention relates to a liposome composition having a polynucleotide entrapped therein, and to a method of preparing the liposome composition.

10

Background of the Invention

In recent years polynucleotides have been studied as possible therapeutic agents due to their ability to alter expression of specific genes. Gene therapy to add a gene function which is missing or absent and to inhibit expression of a gene are under investigation. In particular, 15 gene therapy with antisense oligonucleotides is being widely studied. Oligonucleotides are composed of a string of nucleotide residues complementary to the mRNA of a target gene for hybridizing by Watson-Crick base pairing. In this way, inhibition of translation is achieved, often by mechanisms such as activation of RNase H or by prevention of the assembly or the progress of the translational machinery (Branch, A.D., *Hepatology* 24(6):1517-1529 (1996)).

20

One problem with the use of polynucleotides, DNA, RNA and oligonucleotides, as therapeutic agents is a relatively poor ability to cross the cell membrane in order to reach their site of action in the cytoplasm. Polynucleotides carry a negative charge and, therefore, do not readily cross the cell membrane in free form.

25

Another problem is that polynucleotides can interact with a variety of extracellular molecules which can alter the polynucleotide's bioavailability. Further, polynucleotides are susceptible to degradation in biological fluids and they display pharmacokinetics which may not be favorable for some therapeutic applications.

30

One approach to overcoming these problems is to administer the polynucleotide in the presence of a lipid vesicle, such as a liposome, and various liposome-based compositions have been proposed (Zelphati, O., and Szoka, F.C., *J. Control. Res.* 41:99-119 (1996)). For example, one proposed composition consists of a polynucleotide mixed with pre-formed cationic liposomes. Such liposomes are generally prepared from a cationic lipid mixed with an approximately equimolar concentration of a membrane destabilizing lipid and/or a neutral lipid, such as dioleoylphosphatidyl-ethanolamine (DOPE). The polynucleotide is mixed with the pre-formed cationic liposomes to form polynucleotide-liposome complexes through electrostatic

35

charge interactions. Such complexes have some *in vitro* ability to mediate cellular uptake of polynucleotides, however, the relatively large size (200-2000 nm) and poor stability make them unsuitable for *in vivo* applications, in particular for delivery to organs other than the liver and the lungs (Bennet, C.F., *et al.*, *J. Control. Rel.* 41:121-130 (1996); Litzinger, D.C., *et al.*, *Biochim. Biophys. Acta* 1281:139-149 (1996)).

Another proposed polynucleotide-liposome composition includes a polynucleotide entrapped in the aqueous interior of neutral liposomes formed from neutral vesicle-forming lipids. These liposomes are typically prepared by either hydrating a dried lipid film with a highly concentrated solution of the polynucleotide (Juliano, R.L., and Akhtar, S., *Antisense Res. Dev.* 2:165-176 (1992)) or by the reverse evaporation method (REV) (Ropert, C., *et al.*, *Pharm. Res.* 10(10):1427-1433 (1993); Szoka, F.C., and Papahadjopoulos, D., *Proc. Natl. Acad. Sci. USA* 75(9):4194-4198 (1978)). A problem with polynucleotide-liposome compositions prepared by these methods is a low trapping efficiency of the polynucleotide, in particular for small unilamellar vesicles (<100 nm), where trapping efficiencies on the order of 2-4 % have been reported (Zelphati, O., *et al.*, *Antiviral Res.* 25:13-25 (1994)). Because polynucleotides are expensive, such low trapping efficiencies are unacceptable. The problem is compounded in that recovery of unentrapped polynucleotide can be costly and/or time consuming.

Summary of the Invention

Accordingly, it is an object of the invention to provide a composition for *in vivo* administration of a polynucleotide, where the polynucleotide is entrapped in the central core of a liposome.

It is another object of the invention to provide a method for preparing such a composition which achieves a high trapping efficiency of the polynucleotide in the liposome.

It is another object of the invention to provide a liposome composition that is stable *in vivo*, as evidenced by absence of aggregation of the liposomes in *in vitro* testing.

It is another object of the invention to provide a liposome composition having a long blood circulation lifetime and an entrapped polynucleotide.

In one aspect, the invention includes a liposome composition for *in vivo* administration of a polynucleotide. The composition includes a suspension of liposomes composed predominantly of liposomes having a bilayer membrane formed of a cationic vesicle-forming lipid and a neutral vesicle-forming lipid. The liposomes have a central core with an inner surface, and entrapped in the core and localized predominantly on the inner surface is the polynucleotide.

In one embodiment, the polynucleotide is DNA, RNA, or a fragment or an analog thereof.

In another embodiment, the polynucleotide is an antisense oligonucleotide.

The cationic lipid is, for example, 1,2-dioleoyloxy-3-(trimethylamino) propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE); N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3 β [N-(N',N'-dimethylaminoethane) carbamoly] cholesterol (DC-Chol); or dimethyldioctadecylammonium (DDAB).

The neutral vesicle-forming lipid is, in one embodiment, a phospholipid. In another embodiment, the neutral lipid is derivatized with a hydrophilic polymer, such as polyethylene glycol.

Typically, the liposomes have sizes of less than 300 nm, preferably between about 50-300 nm.

In another embodiment, the liposomes further include a ligand for targeting the liposomes to a selected site in the body, such as a particular tissue region or cell.

In another aspect, the invention includes a method of entrapping a polynucleotide in liposomes. The method includes forming polynucleotide-cationic lipid particles in a lipid solvent suitable for solubilization of the cationic lipid. Neutral vesicle-forming lipids are added to the lipid solvent containing the particles, and the lipid solvent is evaporated to form liposomes having the polynucleotide entrapped therein.

The polynucleotide-cationic particles, in one embodiment, are formed by dissolving the polynucleotide in a non-ionic solvent which is immiscible with the lipid solvent. The dissolved polynucleotide is contacted with a charge-neutralizing amount of cationic lipid solubilized in the lipid solvent in the presence of a third solvent effective to form a single phase solvent system, *e.g.*, a monophase. Additional non-ionic solvent or lipid solvent is added to the single phase system under conditions effective to form a two-phase system, and the non-ionic solvent phase is removed.

In one embodiment, the polynucleotide is dissolved in water and is contacted with cationic lipids solubilized in chloroform in the presence of methanol.

Evaporation of the lipid solvent, in one embodiment, includes hydrating with an aqueous medium.

In another aspect, the invention includes a method of administering a polynucleotide to a subject by administering to the subject a suspension of liposomes as described above.

These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying

drawings.

Brief Description of the Figures

Fig. 1 is a schematic illustration showing formation of liposomes in accordance with the invention by an extraction and evaporation procedure;

Fig. 2 is a plot showing the amount of oligonucleotide recovered, in μ g, upon extraction into an organic phase containing varying amounts of the cationic lipid dioleoyl trimethylammonium propane (DOTAP), where the plus symbols/solid line indicates the amount of oligonucleotide in the aqueous phase and the open triangles/dashed line shows the amount of oligonucleotide in the organic phase;

Fig. 3 is a density gradient profile for cationic labelled lipid (solid line) and polynucleotide (dashed line), shown as the percentage of total counts against fraction number;

Figs. 4A-4B are fractionation profiles following separation down a Sepharose column of a liposome composition with an entrapped polynucleotide in accordance with the invention (Fig. 4A) and a comparative liposome composition formed of neutral vesicle-forming lipids (Fig. 4B);

Fig. 5 is a plot showing the percentage of injected dose in the blood as a function of time following intravenous injection into mice of free oligonucleotide (open circles), oligonucleotide entrapped in neutral liposomes (closed triangles) and in cationic liposomes prepared in accordance with the invention (plus symbols);

Figs. 6A-6C are plots showing the biodistribution of an oligonucleotide following intravenous administration to mice in the free form (Fig. 6A), entrapped in neutral liposomes (Fig. 6B) and entrapped in liposomes in accordance with the invention (Fig. 6C); and

Fig. 7 is a plot showing the reticuloendothelial system uptake of different quantities of an oligonucleotide entrapped in liposomes in accordance with the invention following intravenous administration to mice.

Detailed Description of the Invention

30 I. Liposome Preparation and *In Vitro* Characterization

The liposome composition of the invention is composed of liposomes, typically in suspension form, having a polynucleotide entrapped in the central core. As will be described below and will be apparent from the method of preparation, the liposomes have a lipid bilayer composed of a cationic vesicle-forming lipid and a neutral vesicle-forming lipid. The entrapped

polynucleotide is associated with the cationic vesicle-forming lipid and is localized predominantly on the inner surface of the central core compartment of each liposome.

With reference to Fig. 1, a method for preparing the liposome composition of the invention is illustrated. In the method, a polynucleotide-cationic lipid particle is formed by extracting 5 the polynucleotide through a Bligh and Dyer monophase (Bligh, E.G., and Dyer, W.J., *Can. J. Biochem. Physiol.* 37(8):911-917 (1959)). The polynucleotide is dissolved in a first solvent, typically a non-ionic solvent, at a selected concentration. Exemplary first solvents include deionized water and non-aqueous, hydrophilic solvents. The non-ionic solvent may contain a non-electrolyte solute, such as sucrose, glucose, dextran and the like.

10 A cationic lipid of choice is solubilized in a suitable second solvent, also referred to herein as a lipid solvent, which is immiscible with the first solvent in which the polynucleotide is dissolved. For example, the lipid solvent can be chloroform, tetrachloromethane, trichloroethylene, trichloroethane, benzene, hexane, pentane, toluene and the like.

15 The dissolved polynucleotide and cationic lipid are brought in contact in the presence of a third solvent effective to form a monophase, *e.g.*, a single phase solvent system (tube #2 in Fig. 1). Such a third solvent can be an alcohol, such as methanol or ethanol, a ketone, such as acetone, or an ether. Solvents suitable for the third solvent, *e.g.*, a solvent effective to form a monophase in the presence of the first solvent and the second lipid solvent, can be determined by solubility experiments readily performed by those of skill in the art.

20 With continuing reference to Fig. 1, the monophase is incubated and an amount of the first solvent and/or the lipid solvent is added to separate the monophase into a two-phase solvent system (tube #3 in Fig. 1). The less dense solvent is removed from the system by aspirating or decanting. It will be appreciated that at this point, each phase can be analyzed for 25 polynucleotide content to determine the extraction efficiency, which is indicative of the liposome loading efficiency.

At this point in the method of preparation, a particle referred to herein as a polynucleotide-cationic lipid particle is formed. It will be appreciated that the amounts of polynucleotide and cationic lipid can be selected to achieve a charge-neutralized polynucleotide-cationic lipid particle or a charged particle. As will be discussed below, studies in support of the invention 30 show that the uptake of the liposomes by the reticuloendothelial system are affected by the degree of charge interaction between the cationic lipid and the anionic polynucleotide.

As illustrated in tube #4 of Fig. 1, neutral vesicle-forming lipids are added to the organic phase containing the polynucleotide-cationic lipid particles. An amount of non-ionic solvent is added and the mixture is mixed briefly by vortexing and/or sonication. The organic phase

is then evaporated under rotary evaporation to form a gel phase (tube #5 in Fig. 1). After sufficient evaporation of the organic phase, the system reverts into the aqueous phase to form liposomes having a bilayer lipid membrane of the neutral vesicle-forming lipids and the cationic lipids with the polynucleotide entrapped in the central core of the liposomes. The neutral 5 vesicle-forming lipids are predominantly in the outer lipid bilayers, with the cationic lipids in the inner lipid bilayers closest to the central core of the liposomes. The polynucleotide, which is associated with the cationic lipids, is predominantly on the inner surface regions of the central core compartment.

In studies performed in support of the invention, a polynucleotide-cationic lipid complex 10 was prepared using antisense oligonucleotides having 18 and 21 residues. Example 1 describes preparation of polynucleotide-cationic lipid particles composed of a 18-residue oligonucleotide and the cationic lipid dioleoyl trimethylammonium propane (DOTAP). In this study, the amount of DOTAP required to balance the charge of the 18-mer oligonucleotide was determined. As described in Example 1, a fixed amount of the oligonucleotide, including a 15 trace of ¹²⁵I-oligonucleotide, was dissolved in a non-ionic solvent (deionized water) and mixed with varying amounts of DOTAP dissolved in chloroform. An amount of methanol sufficient to form a monophase was added. After incubation, the monophase mixture was disrupted to form a biphasic solvent system by addition of water and chloroform.

The aqueous phase and the organic phase were analyzed for labelled oligonucleotide and 20 the results are shown in Fig. 2, which shows the amount of ¹²⁵I-oligonucleotide in the organic phase (open triangles/dashed line) and in the aqueous phase (plus symbols/solid line) as a function of nmoles of cationic lipid, DOTAP. As seen, at low cationic lipid concentrations, most of the oligonucleotide remained in the non-ionic, aqueous phase. As the concentration of cationic lipid increased, more oligonucleotide is recovered in the lipid organic phase and at 25 about 80 nmoles of DOTAP, essentially all of the oligonucleotide is extracted into the organic, lipid solvent. At this point, the molar ratio of oligonucleotide to cationic lipid is about 1:50 and the +/- charge ratio is 3:1.

Other studies performed in support of the invention were performed to illustrate the effect 30 of the solvents on the extraction procedure for formation of the polynucleotide-cationic lipid particles. In these studies the procedure described in Example 1 was performed using an ionic aqueous solvent, Hepes buffer (25 mM Hepes, 140 mM NaCl, pH 7.4). In the presence of the ionic buffer, the oligonucleotide was not extracted into the organic phase, presumably due to a charge-shielding interaction. In other studies, a 10% aqueous sucrose solution was used for the extraction with results similar to those described in Fig. 2.

It will be appreciated that the procedure described above for a 18-residue oligodeoxynucleotide and the cationic lipid DOTAP can be used for any selected polynucleotide and cationic lipid combination. Exemplary polynucleotides include DNA, RNA and fragments and analogs thereof; oligonucleotides of up to about 100 nucleotide residues, including 5 oligonucleotides with nuclease resistant chemical linkages, such as phosphorothioate and methylphosphonate.

It will be appreciated that in embodiments where the polynucleotide is, for example, DNA, the polynucleotide can be condensed using a polycationic condensing agent in addition to or instead of the cationic lipid. For example, spermine, spermidine, histones, poly-lysine and 10 protamine sulfate are polycationic agents suitable for condensing a large polynucleotide to facilitate its entrapment in the liposomes of the invention.

Cationic lipid as used herein refers to a vesicle-forming lipid having a net positive charge. The cationic lipid can be a monocation or a polycation. As defined herein, "vesicle-forming lipid" is intended to include any amphipathic lipid having hydrophobic and polar head group 15 moieties, and which by itself can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids. Typically, such vesicle-forming lipids are diacyl-chain lipids, such as a phospholipid, whose acyl chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.

Exemplary cationic vesicle-forming lipids include phospholipids, such as 20 phosphatidylethanolamine, whose polar head groups are derivatized with a positive moiety, e.g., lysine, as illustrated, for example, for the lipid DOPE derivatized with L-lysine (LYS-DOPE) (Guo, L., et al., *Journal of Liposome Research* 3(1):51-70 (1993)). Also included in this class are the glycolipids having a cationic polar head-group. Another cationic vesicle-forming lipid which may be employed is cholesterol amine and related cationic sterols.

25 Other examples include 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide (DORIE); N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3 β [N-(N',N'-dimethylaminoethane) carbamoly] cholesterol (DC-Chol); and dimethyldioctadecylammonium 30 (DDAB).

The above-described lipids can be obtained commercially, or prepared according to published methods.

A variety of neutral lipids are suitable for use in the present invention. Neutral vesicle-forming lipids, meaning vesicle forming lipids which have no net charge, include phos-

pholipids, such as phosphatidylcholine, phosphatidyl ethanolamine, phosphatidylinositol, and sphingomyelin. Negatively charged lipids are also contemplated for use alone or in combination with a neutral lipid. Exemplary negative vesicle-forming lipids include phosphatidylserine, phosphatidylglycrol and phosphatidic acid. It will be appreciated that other 5 lipids, such as cholesterol and other uncharged sterols, can be added to the neutral or negatively charged vesicle-forming lipid and that various combinations are suitable for use.

Example 2 describes formation of liposomes following formation of oligonucleotide-cationic lipid particles by the extraction procedure discussed above in Example 1. Cationic lipid-oligonucleotide particles were prepared using the cationic lipid DOTAP and a 21-residue 10 oligonucleotide by dissolving 50 μ g of the oligonucleotide in a non-ionic aqueous phase and 0.5 μ moles DOTAP in a lipid organic phase. The oligonucleotide was extracted from the aqueous phase to form oligonucleotide-cationic lipid particles.

Added to the oligonucleotide-cationic lipid particles was a selected amount of phosphatidylcholine (iodine number 40) and cholesterol in a 2:1 ratio (PC:chol). A small 15 amount of deionized water was added, the mixture was sonicated briefly to emulsify the phases and the organic phase was evaporated. Liposomes formed once the system reverted into the aqueous phase. As described above, the entrapped oligonucleotides are associated predominantly with the inner surface of the central core region due to the charge interaction between the cationic lipid and the oligonucleotides. The neutral lipids coat the particles, to 20 form a liposomal bilayer composed of both the cationic lipids, which are primarily disposed in the inner bilayer region of the liposomes, and the neutral lipids, which are disposed in the outer bilayer regions of the liposomes and form a coating around the cationic-polynucleotide particles.

Liposomes having entrapped oligonucleotides, prepared as described in Example 2, were 25 characterized by dynamic light scattering and on a metrizamide density gradient column to determine encapsulation efficiency. As described in Example 3, the suspension of liposomes was placed on a metrizamide gradient column to separate the liposomes containing entrapped oligonucleotide from untrapped oligonucleotide. Untrapped oligonucleotide equilibrates in a lower, more dense column fraction, *e.g.*, the 20% metrizamide fraction whereas the 30 liposomes equilibrate in a less dense fraction. After the liposomes sample was placed on the column, the gradient column was centrifuged. After centrifugation, the liposome fraction of the sample had equilibrated at the 10% metrizamide/water interface, with a faint band of lipid visible at the 20%/10% metrizamide interface. The lipid was collected from the 10% metrizamide/water interface for counting in a gamma counter and for assaying for phosphate

content.

Table 1

5	Phosphatidylcholine (μ moles)	Size* (nm)	Encapsulation Efficiency* (%)	Polynucleotide/phospholipid Ratio* (nmol/ μ mol)
10	0.5	360 \pm 60	72 \pm 10	7.9 \pm 2.1
	1.0	530 \pm 170	74 \pm 4	5.4 \pm 0.4
	2.0	510 \pm 200	73 \pm 10	3.4 \pm 0.5

*value \pm standard deviation for n=3.

10

Table 1 shows the results for three liposomal compositions containing different amounts of phosphatidylcholine. The encapsulation efficiency, taken as the counts in the liposome-associated oligonucleotide fraction over the total number of counts measured in the column, is around 73%, a significant improvement over that achieved by passive entrapment.

15

Also shown in Table 1 are the liposomal particle size measurements, determined by dynamic light scattering. The liposomes were between 360-530 nm in diameter, somewhat larger than preferred for *in vivo* administration, where liposomes having sizes of less than about 300 nm are preferred. Sizing of the liposomes down to the preferred size was demonstrated by extruding through 100 nm or stacked 200 nm filters. These extrusions demonstrated that the 20 liposomes can be successfully down-sized while retaining the entrapped oligonucleotide. The extrusion experiments also demonstrated that the neutral lipid stabilizes the liposomes, as evidenced by liposomes having about 2 μ moles neutral lipid were more stable during the extrusion.

20

In one embodiment of the invention, the liposomes include a surface coating of hydrophilic 25 polymer chains, effective to extend the blood circulation time of the liposomes. Suitable hydrophilic polymers include polyethylene glycol (PEG), polylactic acid, polyglycolic acid, polyvinyl-pyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethyl-cellulose. A preferred hydrophilic polymer chain 30 is polyethyleneglycol (PEG), preferably as a PEG chain having a molecular weight between 500-10,000 daltons, more preferably between 1,000-5,000 daltons.

30

The coating is preferably prepared by including in the neutral vesicle-forming lipids forming the liposomes, between 1-20 mole percent of a vesicle-forming lipid, preferably a phospholipid or other diacyl-chain lipid, derivatized at its head group with the polymer chain. 35 Exemplary methods of preparing such lipids, and forming polymer coated liposomes therewith,

have been described in co-owned U.S. Patents Nos. 5,013,556, 5,631,018 and 5,395,619, which are incorporated herein by reference. The polymer may be stably coupled to the lipid, or coupled through an unstable linkage which allows the coated particles to shed their coating as they circulate in the bloodstream.

5 Liposomes having such a surface coating and including an entrapped polynucleotide were prepared using methoxy polyethylene glycol (mPEG) derivatized to distearoyl phosphatidylethanolamine (DSPE). As described in Example 3, oligonucleotide-cationic lipid particles were formed and liposomes were prepared by adding to the particles neutral lipids composed of a 2:1:0.1 molar ratio of phosphatidylcholine, cholesterol, and mPEG₂₀₀₀ covalently 10 attached to the polar head group of DSPE, mPEG-DSPE. The resulting liposome suspension was extruded through polycarbonate filters to diameters below 200 nm.

15 The encapsulation efficiency of the oligonucleotide into the PEG-coated liposomes was determined by separating the liposomes from unentrapped oligonucleotide on a metrizamide gradient, as described in Example 3. The separation profile of the liposome suspension is shown in Fig. 3, where the percentage of total counts on the gradient column is shown as a function of fraction number. As seen in the figure, nearly all of the lipid migrated to the 10% metrizamide/deionized H₂O interface, and except for a very small amount in the first two fractions, all of the oligonucleotide migrated with the lipid. Table 2 summarizes the results from two separate experiments.

20

Table 2

Neutral Lipid Added (μmoles)	Size (nm)	Encapsulation Efficiency (%)	Ratio* oligonucleotide/phospholipid (nmol/μmol)
3	174	86	2.1
3	176	91	2.2

*Calculated based on the starting oligonucleotide:phospholipid ratio, and then correcting for % of oligonucleotide not associated with lipid.

30

The data in Table 2 shows that for a liposome having a size of about 175 nm, a size suitable for *in vivo* administration, the encapsulation efficiency was around 90%, a considerable improvement over the 10% efficiency reported in the literature for liposomes prepared by other procedures (Ropert, *et al.*, 1993). The oligonucleotide to phospholipid 35 ratio is around 2 nmol/μmol.

In another embodiment of the invention, the liposomes include a ligand or affinity

moiety effective to bind specifically to a desired tissue region or target cell. Such moieties can be attached to the surface of the liposome or to the distal ends of hydrophilic polymer chains. Exemplary moieties include antibodies, ligands for specific binding to target cell surface receptors and the like, as described, for example, in co-owned PCT application No.

5 WO US94/03103.

A. Liposome Stability

The stability of the liposomes in 25% fetal bovine serum was determined by preparing liposomes having an entrapped oligonucleotide and measuring liposome size as a function of time after placing in the serum.

10 In this study, the liposomes were prepared in accordance with the method of the invention and were composed of a 21-residue oligodeoxynucleotide, the cationic lipid DOTAP, and neutral lipids consisting of 5 mol% mPEG-DSPE, 2 μ moles phosphatidylcholine and 1.25 μ moles cholesterol (PC:Chol:mPEG-DSPE molar ratio of 2:1:0.1).

15 Two liposome suspensions were prepared using these components. In the first liposome suspension, deionized water was used for formation of the cationic-lipid-oligonucleotide particles and as the hydration medium for liposome formation during solvent evaporation. In the second suspension, a 5% sucrose aqueous solution was used rather than water.

20 The size of the liposomes after extrusion was 174 nm, for the liposomes prepared in deionized water, and 172 nm, for the liposomes prepared in 5% sucrose, as seen in Table 3.

25 A sample of each liposome suspension was placed in buffer (25 mM Hepes, 140 mM NaCl, pH 7.4) and the particle size was measured again, as seen in Table 3. The liposomes in both suspensions were reduced in size, to around 156 nm and 157 nm for the water-based and the 5% sucrose-based suspensions, respectively.

30 A sample of each liposome suspension was placed in a solution of 25% fetal bovine serum in buffer and the liposome particle size was measured immediately and at 24 hour intervals after storing at 37°C. As seen in Table 3, the liposomes in each suspension experience some change in particle size as the particles equilibrate to balance the inner and outer osmotic strengths. Importantly, no aggregation of the liposomes was observed, indicating that the liposomes should be stable after *in vivo* administration.

Table 3

Tube #	Neutral Lipid (μ moles)	Aqueous Phase	Size After Extrusion (nm)	Size in Hepes 7.4 (nm)	Size in 25% FBS (nm)		
					0 hrs.	24 hrs.	48 hrs.
5	1	2 deionized H_2O	174	156	171	160	165
	2	5% sucrose	172	157	226	166	198

II. In vivo Characterization of the Liposomes

Liposomes were prepared in accordance with the invention to include an 18-mer phosphorothioate oligonucleotide complementary to the *MDRI* gene. The liposomes used for the *in vivo* studies included a surface coating of polyethylene glycol (PEG) hydrophilic polymer chains, by including in the neutral liposome composition distearoyl phosphatidylethanolamine derivatized with PEG (mPEG₂₀₀₀-DSPE), as described in Example 5B. For comparison, neutral liposomes were prepared by a conventional lipid film hydration in the presence of the oligonucleotide (Example 5A).

Figs. 4A-4B are fractionation profiles for the cationic liposomes (Fig. 4A) and the neutral liposomes (Fig. 4B) prepared for the animal studies. The profiles were obtained by sampling the fractions during separation of the free oligonucleotide from the lipid associated oligonucleotide by filtration down a Sepharose CL-4B column (Example 5B). As seen in Fig. 4A, virtually 100% of the oligonucleotide was associated with the lipid fraction, as evidenced by the single elution peak over fractions 5-12. In contrast, as seen in Fig. 4B, only 20% of the oligonucleotide was associated with the neutral liposomes.

The liposomes were sized by dynamic light scattering and the conventional liposomes had an average diameter of 197 ± 2 nm (polydispersity 0.032 ± 0.012) while the cationic liposomes of the invention had an average diameter of 188 ± 1 nm (polydispersity 0.138 ± 0.018).

Both liposome compositions were administered to mice according to the procedure of Example 6. Free oligonucleotide was also administered to a group of test animals. The compositions were intravenously administered in a single bolus injection via the tail vein at a lipid (phosphatidylcholine) dose of 0.5μ moles. At specific time points three mice from each test group were sacrificed and the organs and a blood sample were analyzed for presence of oligonucleotide.

Fig. 5 shows the blood circulation lifetime of the free oligonucleotide (open circles) and the liposome entrapped oligonucleotide, where the liposomes of the invention are

represented by the plus symbols and the comparative, neutral liposomes by the closed triangles. As seen in the figure, free ^{125}I -labelled oligonucleotide has an initial, rapid distribution phase and approximately 50% of the injected dose has been eliminated from the body 2 hours after administration.

5 In contrast, ^{125}I -labelled oligonucleotide encapsulated within liposomes demonstrate a much different pharmacokinetic profile in the blood. Encapsulated within neutral liposomes (closed triangles), the oligonucleotide has a short initial phase of elimination immediately following injection which accounts for about 10% of the injected dose. The remaining 90% of the dose has a much slower rate of elimination, so that at 24 hours following injection, 10 about 20% of the injected dose remains in blood.

^{125}I -labelled oligonucleotide entrapped within the cationic liposomes of the invention displayed a similar profile, however, the initial phase of elimination accounted for approximately 30% of the injected dose. Twenty-four hours following injection, over 10% of the injected dose remained in the blood.

15 Table 4 gives the pharmacokinetic parameters calculated for each treatment. The residence time corresponds to the time required for 66% of the administered dose to be eliminated from the blood, and the liposome formulations result in a significant improvement in residence time. The area under the curve (AUC) values for the liposome formulations are also significantly higher than for the free oligonucleotide. The AUC for oligonucleotide entrapped within the liposomes of the invention is larger than for neutral 20 liposomes because of the larger dose administered (52.4 μg versus 6.5 μg). As discussed above, the dose administered was based on the amount of lipid rather than amount of oligonucleotide, since the lipid dose can have a significant effect on liposomal pharmacokinetics (Allen, T.M. *et al.*, *Biochim. Biophys. Acta* 1068:133-141 (1991)) when 25 the entrapped agent has a slow rate of leakage from the liposomes. The amount of oligonucleotide associated with the cationic liposomes is significantly greater than for neutral liposomes, as demonstrated by the entrapment efficiency (Figs. 4A, 4B) and therefore the amount of oligonucleotide injected per μmole phospholipid is much greater for the cationic liposomes, leading to a larger AUC. When doses are normalized to 30 μg 30 oligonucleotide/mouse (assuming linear pharmacokinetics), the AUC for neutral liposomes (199.9) is greater than for cationic liposomes (128.1) or free oligonucleotide (10.4). It will be appreciated that the improved loading efficiency of the oligonucleotide in the cationic liposomes of the invention permit administration of a smaller lipid dose to achieve a given dose of oligonucleotide, compared to conventional neutral liposomes.

With continuing reference to Table 4, the rapid clearance of free oligonucleotide from the blood is also reflected in the elimination rate constant (k) which is more than 10-fold greater than for both liposomal treatments. The volume of distribution (V_D) for both liposomal treatments is close to the blood volume of the animals used, however, for free oligonucleotide the volume of distribution was about 5-fold higher, indicating that it was widely distributed within the tissues.

The blood circulation half-lives ($T_{1/2}$) for the initial phase of elimination ($T_{1/2\alpha}$) and for the elimination of the remaining dose ($T_{1/2\beta}$) are also shown in Table 4.

10 Table 4
15 Pharmacokinetic parameters calculated for
20 oligonucleotide in different formulation

Group	Residence Time (hrs)	AUC ($\mu\text{g}\cdot\text{hr}/\text{ml}$)	V_D (ml)	k (hr^{-1})	$T_{1/2\alpha}$ (hrs)	$T_{1/2\beta}$ (hrs)
Neutral liposomes (6.5 μg)	17.6	43.4	1.96	0.08	0.39	12.4
cationic liposomes (52.4 μg)	15.0	226.9	2.39	0.10	0.26	10.6
Free oligonucleotide (30 μg)	4.7	5.7	13.77	0.38	0.26	3.5

25 Figs. 6A-6C are plots showing the biodistribution of the oligonucleotide in the animals, where Fig. 6A corresponds to the distribution after administration of the oligonucleotide in the free form, Fig. 6B corresponds to the oligonucleotide entrapped in neutral liposomes and Fig. 6C corresponds to the oligonucleotide entrapped in cationic liposomes in accordance with the invention.

30 Fig. 6A shows that very little free oligonucleotide remains in blood any time point after 15 minutes. The greatest proportion of the dose distributes to the carcass which includes all of the remaining tissues left undissected. The liver and kidney also contained significant amounts of radioactive counts.

35 Fig. 6B shows that at all time points, the greatest proportion of oligonucleotide exists in the blood when administered in the form of neutral liposomes. Blood levels account for nearly all of the dose, particularly at the earlier time points. There is a relatively constant amount in the liver and spleen at all time points, however, carcass levels appear to increase in later time points and this would be consistent with the distribution and elimination of free

oligonucleotide following release from the liposomes, or possible the accumulation of liposomal oligonucleotide within tissues.

Fig. 6C shows that oligonucleotide administered entrapped in cationic liposomes the nucleotide remains primarily in the blood. There is an increase in carcass levels over time, 5 consistent with elimination of free oligonucleotide or with the accumulation of liposomal oligonucleotide in the tissues.

In another study, the effect of the oligonucleotide:cationic lipid ratio on uptake of the liposomes by the reticuloendothelial system was studied. Liposomes were prepared by the method of the invention (Example 5B) with ratios of oligonucleotide:cationic lipid (DOTAP) 10 of 0 (no oligonucleotide in the formulation), 44.4 $\mu\text{g}/\mu\text{mole}$ (+/- ratio of 2.6:1) and 104.8 $\mu\text{g}/\mu\text{mole}$ (+/- ratio 1.1:1). In the formulation where the liposomes contained no oligonucleotide, the liposomes were hydrated in the presence of ^{125}I -labelled tyraminylinulin, prepared as described in Sommerman (Sommermann E.F., *et al.*, *Biochem. Biophys. Res. Comm.*, 122:319-324 (1984)). The liposome formulation were intravenously injected into 15 mice and the liver and spleen were analyzed 15 minutes after administration for ^{125}I -labelled tyraminylinulin and ^{125}I -labelled oligonucleotide.

The results are shown in Fig. 7 where the percentage of remaining dose in the 20 reticuloendothelial system is shown as a function of oligonucleo-tide/cationic lipid ratio. For the dose with no oligonucleotide, nearly 50% of the dose distributed to the liver and spleen 15 minutes following injection. When the oligonucleotide/cationic lipid ratio was 44.4 $\mu\text{g}/\mu\text{mole}$, approximately 40% of the dose distributed to liver and spleen. When the ratio was 104.8 $\mu\text{g}/\mu\text{mole}$ (+/- ratio 1.1:1), approximately 30% of the dose distributed to the liver and spleen 15 minutes following injection. The uptake at 104.8 $\mu\text{g}/\mu\text{mole}$ was significantly different from the uptake at 44.4 $\mu\text{g}/\mu\text{mole}$ and 0 $\mu\text{g}/\mu\text{mole}$ ($p < 0.05$).
25

III. Method of Administration

In another aspect, the invention includes a method of administering a polynucleotide to a subject. The polynucleotide is entrapped in cationic liposomes as described above and administered to a subject in need of treatment.

30 The polynucleotide entrapped in the liposomes can be selected from a variety of DNA and RNA based polynucleotides, including fragments and analogues of these. In one embodiment, the polynucleotide is an antisense DNA oligonucleotide composed of sequences complementary to its target, usually a messenger RNA (mRNA) or a mRNA precursor. The mRNA contains genetic information in the functional, or sense, orientation

and binding of the antisense oligonucleotide inactivate the intended mRNA and prevents its translation into protein. Such antisense molecules are determined based on biochemical experiments showing that proteins are translated from specific RNAs and that once the sequence of the RNA is known, an antisense molecule that will bind to it through complementary Watson-Crick base pairs can be designed. Such antisense molecules typically contain between 10-30 base pairs, more preferably between 10-25, and most preferably between 15-20.

5 In one embodiment of the invention, the antisense oligonucleotide is modified for improved resistance to nuclease hydrolysis. Such analogues include phosphorothioate, 10 methylphosphonate, phosphodiester and p-ethoxy oligonucleotides (WO 97/07784, published 6 March 1997).

10 The composition of the invention is intended for use in a variety of therapies, including, but not limited to, treatment of viral, malignant and inflammatory diseases and conditions, such as, cystic fibrosis, adenosine deaminase deficiency and AIDS. Treatment of cancers 15 by administration of tumor suppressor genes, such as APC, DPC4, NF-1, NF-2, MTS1, RB, p53, WT1, BRCA1, BRCA2, VHL, or administration of oncogenes, such as PDGF, erb-B, erb-B2, RET, ras (including Ki-ras, N-ras), c-myc, N-myc, L-myc, Bcl-1, Bcl-2 and MDM2, are contemplated.

15 Adminstration of the following nucleic acids for treatment of the indicated conditions are also contemplated: HLA-B7, tumors, colorectal carcinoma, melanoma; IL-2, cancers, especially breast cancer, lung cancer, and tumors; IL-4, cancer; TNF, cancer; IGF-1 antisense, brain tumors; IFN, neuroblastoma; GM-CSF, renal cell carcinoma; MDR-1, cancer, especially advanced cancer, breast and ovarian cancers; and HSV thymidine kinase, brain tumors, head and neck tumors, mesothelioma, ovarian cancer.

20 25 It will be appreciated that the composition of the invention has utility in *ex vivo* procedures as well.

30 The liposomes are typically in suspension form, for parenteral administration, preferably intravenous administration. Other routes of administration are suitable, including subcutaneous, intramuscular, interlesional (to tumors), intertracheal by inhalation, topical, internasal, intraocular, via direct injection into organs and intravenous.

From the foregoing, it can be appreciated how various features and objects of the invention are met. The present invention provides a liposome composition having a polynucleotide entrapped in the central core, where, by virtue of the method of preparation, the polynucleotide is associated primarily with the inner surface region of the cationic lipids

forming the central core. A coating of neutral lipids surrounds the cationic lipid core, the neutral lipids serving to stabilize the vesicles.

5 In the embodiment where the liposomes include a surface coating of hydrophilic polymer chains, the liposomes achieved a long blood circulation lifetime, with little uptake by the RES.

Further, the method for preparing the liposomes results in a high encapsulation efficiency of the polynucleotide, where at least about 80% of the polynucleotide is entrapped in the liposomes. In the studies described above, at a 1:1 charge ratio of 10 oligonucleotide:cationic lipid, approximately 95% of the oligonucleotide was extracted from the aqueous phase into the organic phase. Following addition of neutral lipid and liposome formation all of the oligonucleotide remains associated with the lipid (as evidenced by Fig. 4A).

15 The liposomes can be sized by extrusion, if necessary, to bring the liposome size to a range suitable for *in vivo* administration, typically, less than about 300 nm, more preferably between 50-300 nm, most preferably between 100-200 nm. The liposomes are stable, as evidenced by no aggregation or appreciable change in size when placed in fetal bovine serum and by low lung and RES uptake *in vivo*.

IV. EXAMPLES

20 The following examples illustrate the liposome composition and method of preparation of the present invention. The examples are in no way intended to limit the scope of the invention.

25 Example 1
Formation of Polynucleotide-Cationic Lipid Particles

A. Preparation of ^{125}I -labelled oligonucleotide

^{125}I -labelled oligonucleotide was prepared in the following way: a 1ml conical reaction vial was coated with approximately 200 μg of Iodogen (Pierce, Rockford, IL) and then 500 μg of oligonucleotide was added along with 2,400 pmoles of ^{125}I (185 Mbq) and 300 μg of 30 oligonucleotide was added along with 2,400 pmole of ^{125}I (185 Mbq) and 300 μl 0.35 M sodium acetate, pH 4.0 in a total volume of 400 μl (Piatyszek, M.A., *Ana. Biochem.* 172:356-359 (1988)). The mixture was incubated for one hour at 40°C with frequent agitation. Following incubation, the mixture was removed from the reaction vial and free ^{125}I was removed by separation on a Sephadex G-25 column. In order to remove residual 35 free ^{125}I , the sample was precipitated in 0.3 M sodium acetate and 2.5 volumes of 95%

ethanol. Free iodine was discarded in the supernatant while labelled oligonucleotide was rehydrated from the pellet and de-salted on a Sephadex G-25 (Pharmacia, Sweden) column equilibrated in double distilled H₂O. This resulted in less than 5% free ¹²⁵I as determined by thin layer chromatography on PEI-cellulose (J.T. Baker, Inc., Phillipsburg, NJ).

5

B. Extraction Procedure to Prepare Particles

Seven vials containing 10 μ g of an 18-residue oligonucleotide with a trace of ¹²⁵I-oligonucleotide in 0.25 mL distilled deionized water were prepared.

10 The cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) (Avanti Polar Lipids, Alabaster, Alabama) was dissolved in chloroform at concentrations ranging from about 1.8 to 1880 nmoles/ml.

0.25 mL of each chloroform-cationic lipid solution and 0.51 mL methanol were added to each vial of oligonucleotide and each vial was vortexed to form a monophase.

15 After a 30 minute incubation at room temperature, 0.25 mL of distilled, deionized H₂O and 0.25 mL of CHCl₃ were added to each vial to disrupt the monophase, forming a biphasic system in each vial. The vials were mixed and then centrifuged for 7 minutes at 800 \times g. The aqueous-methanol layer was aspirated from each vial and saved in a separate tube, and then the amount of oligonucleotide in both phases was measured by counting in a gamma counter. The results are shown in Fig. 1.

20

Example 2 Preparation of Liposomes

Cationic lipid-oligonucleotide particles were prepared using the procedure of Example 1 by dissolving 50 μ g of a 21-residue oligonucleotide in distilled, deionized water. 0.5 25 μ moles DOTAP was dissolved in chloroform, and the oligonucleotide was extracted into the chloroform according to Example 1.

Following the extraction, phosphatidylcholine (PC, iodine number 40) and cholesterol in a 2:1 ratio (PC:chol) were added to the chloroform organic phase containing the oligonucleotide-cationic lipid particles. Typically, the amount of PC added was 0.5 30 μ moles, 1.0 μ moles or 2.0 μ moles. After addition of the neutral lipids, 0.2 mL of distilled deionized H₂O was added and the mixture sonicated briefly to emulsify the mixture. The organic phase was evaporated in a Roto-vap under a vacuum of 500-700 mmHg.

Liposomes formed once the system reverted into the aqueous phase. The liposomes were typically between 200 and 400 nm in diameter.

35

Example 3
Encapsulation Efficiency of Polynucleotide

A suspension of liposomes was prepared according to Example 2, with the addition of a trace amount of ¹²⁵I labelled oligonucleotide (prepared as in Example 1). The 5 encapsulation efficiency and oligonucleotide:phospholipid ratio was determined as follows.

The encapsulation efficiency was determined by separating the nonentrapped 21-mer oligonucleotide from the liposome-associated oligonucleotide on a metrizamide gradient and measuring by gamma counter the amount of oligonucleotide in each fraction. The 10 encapsulation efficiency was taken as the counts in the liposome-associated oligonucleotide fraction over the total number of counts measured.

The metrizamide gradient was performed as follows. A 20% metrizamide/10% metrizamide/deionized H₂O gradient was set in 12 mL centrifuge tubes by sequentially layering 1.5 mL of 20% metrizamide, 8 mL of 10% metrizamide and 2 mL of deionized H₂O. A control experiment of free oligonucleotide verified that 100% of free, non-lipid 15 associated oligonucleotide remained in the 20% metrizamide fraction.

The liposome samples were placed on the gradient column and the gradients were then centrifuged at 240,000 \times g for 4 hours at 4°C. After centrifugation, a lipid band at the 10% metrizamide/deionized H₂O interface was visible. The lipid was collected from the 10% metrizamide/H₂O interface by aspiration with a pipette and counted in a gamma 20 counter and then assayed for phosphate content. Table 1 gives the results from for three liposomal formulations containing 0.5, 1.0 or 2.0 μ moles phosphatidylcholine.

Example 4
Liposomes with a Surface-Coating
of Polyethylene Glycol

Liposomes having a surface coating of polyethylene glycol (PEG) were prepared 25 according to the procedure described in Example 2 by extracting 50 μ g of oligonucleotide with a trace of ¹²⁵I-oligonucleotide in deionized water with 0.5 μ moles DOTAP in chloroform. Then, 3 μ moles of phosphatidylcholine (PC40), 1.75 μ moles of cholesterol, 30 and 0.175 μ moles of distearoyl phosphatidylethanolamine derivatized with PEG (mPEG₂₀₀₀-DSPE) (PC:Chol:mPEG molar ratio of 2:1:0.1) were added to the organic lipid phase, containing 0.5 μ moles of DOTAP and the extracted oligonucleotide. A trace of ³H-Chol was also added to the organic phase.

Liposomes were prepared from this mixture by evaporation of the chloroform and 35 200 μ L deionized H₂O was added to increase the volume for extrusion. The liposome

suspension was extruded through 400 nm and 200 nm polycarbonate filters to diameters below 200 nm.

The liposome suspension was characterized by separation of the non-entrapped oligonucleotide from the lipid-associated oligonucleotide on a metrizamide gradient as 5 described in Example 3, except for a 12 hour centrifugation time. After centrifugation, the gradients were fractioned carefully by making a small hole in the bottom of the centrifugation tube and collecting the phases in equal drop fractions in scintillation vials. Both γ (for ^{125}I -oligonucleotide) and β (for ^3H -Chol) counts were measured, then β counts for each fraction were corrected for the γ signal. Figure 3 gives a representative gradient 10 profile and the results are summarized in Table 2.

Example 5
Preparation of Liposomes for *in vivo* studies

A. Preparation of Comparative Neutral Liposomes

15 Neutral liposomes encapsulating an 18-mer antisense oligodeoxynucleotide were prepared by hydrating a lipid film in a concentrated solution of the oligonucleotide. Partially hydrogenated soy phosphatidylcholine (PC40), cholesterol and polyethylene glycol distearoyl phosphatidylethanolamine (PEG₂₀₀₀-DSPE) were mixed in chloroform at a molar ratio of 2:1:0.1. The mixture was dried to a thin film by rotary evaporation and then traces 20 of chloroform were removed under vacuum overnight. A solution of 1.7 mM oligonucleotide was added to the lipid film to give a phospholipid concentration of approximately 300 mM, the film was allowed to hydrate for six hours at room temperature. An equal volume of oligonucleotide solution was then added and the tube was vortexed for approximately one minute. Next, the mixture was diluted to 75 mM phospholipid with 25 Hepes buffer (25 mM Hepes, 140 mM NaCl, pH7.4) and sonicated for 2 minutes. The liposomes were then extruded under N₂ pressure through a 200 nm Nuclepore polycarbonate filter in Hepes buffer according to Olson *et al.* (Olson, F., *Biochim. Biophys. Acta* 557:9-23 (1979)). Liposomes were sized by dynamic light scattering using a Brookhaven B190 30 particle sizer (Brookhaven Instrument, Holtsville, NY). Free oligonucleotide was separated from lipid associated oligonucleotide by filtration down a Sepharose CL-4B (Pharmacia, Sweden) column equilibrated with Hepes buffer.

B. Preparation of Cationic Liposomes having a surface coating of PEG

1. Preparation of ^{32}P -labelled oligonucleotide

35 An 18-mer phosphorothioate oligonucleotide complementary to the *MDRI* gene was

synthesized by the University Core DNA Services Lab at the University of Calgary (Calgary, AB). A ^{32}P -labelled oligonucleotide was prepared following the general procedure of Sambrook *et al.* (Sambrook, J. *et al.* (1989) Molecular Cloning: A Laboratory Manual, *Cold Spring Harbor Laboratory Press*, New York.)

5 Briefly, 100 ng oligonucleotide was mixed with 50 μCi ^{32}P - γ -ATP (ICN Pharmaceuticals, Inc., Irvine, CA), 5x's forward reaction buffer and 10 units T4 kinase (Gibco BRL, Gaithersburg, MD) to a total volume of 20 μL . The mixture was incubated at 37°C in a water bath for 45 minutes. Following incubation, 80 μL buffer (10 mM Tris, 1 mM EDTA) was added and then the oligonucleotide was extracted using
10 phenol/chloroform/isoamyl alcohol (25:24:1) (FisherBiotech, Fair Lawn, NJ). Free ^{32}P - γ -ATP was removed by separation on a Sephadex G-50 (Pharmacia, Sweden) spin column.

2. Liposome Preparation

15 The cationic lipid 1,2-Dioleoyl-3-trimethyl ammonium-propane (DOTAP) (Avanti Polar Lipids, Alabaster, Alabama) was used to exact the 18-mer phosphorothioate oligonucleotide through a Bligh and Dyer monophase. Up to 700 μg (approximately 0.118 μmoles) of 18-mer oligonucleotide was diluted in 250 μL double distilled H_2O plus a trace of ^{125}I - or ^{32}P -labelled oligonucleotide. In a separate tube, up to two μmoles of DOTAP were diluted to 250 μL in CHCl_3 and 510 μL of MeOH was added. The oligonucleotide in double distilled
20 H_2O was then added to the CHCl_3 /MeOH mixture containing DOTAP and the sample was mixed to form a monophase. Following 30 minutes incubation at room temperature, 250 μL of CHCl_3 were added, followed by 250 μL of double distilled H_2O . The tube was vortexed briefly and then centrifuged at 900 x g for 7 minutes. The system then existed as a biphasic and the upper, aqueous phase, was removed and the amount of oligonucleotide
25 was determined either by radioactive counts or by measuring the absorbance at 260 nm. This procedure resulted in ~95% of the oligonucleotide being extracted into the organic phase when a 1:1 (+/-) charge ratio was used (DOTAP:oligonucleotide).

Next, partially hydrogenated soy phosphatidylcholine (PC40), cholesterol and mPEG-DSPE (all in CHCl_3) were added to the organic phase to give a molar ratio
30 PC40:Chol:DOTAP:mPEG-DSPE of 3:2:1:0.2. Following transfer into a glass test tube, enough double distilled H_2O was added so that the phospholipid concentration would be 20-30 mM in H_2O and the emulsion was vortexed and then sonicated for approximately one minute. The organic phase was then evaporated off under rotary evaporation at approximately 400 mmHg. The system formed a gel phase following the evaporation of

most of the organic phase and following further evaporation (sometimes with slight agitation), the system reverted into the aqueous phase which was briefly vortexed and then further evaporated. The vesicles formed by this procedure had a diameter in the range of 600 to 800 nm which were subsequently extruded through 400 and then 200 nm
5 polycarbonate filters.

Liposomes were sized by dynamic light scattering using a Brookhaven BI90 particle sizer (Brookhaven Instrument, Holtsville, NY). The neutral liposomes had an average diameter of 197 ± 2 nm (polydispersity 0.032 ± 0.012) while the DOTAP cationic liposomes had an average diameter of 188 ± 1 nm (polydispersity 0.138 ± 0.018). The
10 size was stable in buffer at $4^\circ C$ as well as in 25% FBS at $37^\circ C$ for at least three days (data not shown).

Free oligonucleotide was separated from lipid-associated oligonucleotide by filtration down a Sepharose CL-4B (Pharmacia, Sweden) column equilibrated with Hepes buffer. The fractionation profiles for the cationic liposomes and the neutral liposomes are shown in
15 Figs. 4A and 4B, respectively.

Example 6
In vivo Administration of the Liposomes

20 Female ICR outbread mice (6-8 weeks old) were purchased from Charles River and used within 5 weeks of delivery at which time the weight ranged from 24 to 30 grams. Mice were given a single bolus injection via the tail vein of 0.2 mL of liposomes at a lipid dose of $0.5 \mu\text{moles}$ phospholipid per mouse. Radioactive counts from each injection ranged from 0.4 to 2×10^5 cpm. At specific time points (0.25, 0.5, 1, 4, 12, 24 hours) mice (3
25 per group) were sacrificed, and organs were dissected, weighed, and radioactive counts determined in a Beckman gamma 8000 counter. Liver, spleen, lung, heart, kidney, $100 \mu\text{L}$ blood, and thyroid were dissected and counted, and the remainder of the animal (carcass) was also counted. The radioactive counts in each tissue and the carcass were corrected using blood correction factors which were previously determined, (Allen, T.M., U.C.L.A.
30 Symposium on Molecular and Cellular Biology, in *Lopez-Berestein, G. and Fidler, I., eds.* 89:405-415, Alan R. Liss, New York). Blood counts were extrapolated to the total blood volume of the mouse.

The results for the *in vivo* administration are shown in Figs. 5, 6 and 7.

IT IS CLAIMED:

1. A liposome composition for *in vivo* administration of a polynucleotide, comprising a suspension of liposomes composed predominantly of liposomes having a bilayer membrane formed of a cationic vesicle-forming lipid and a neutral vesicle-forming lipid, said liposomes having a central core with an inner surface, and entrapped in the core and localized predominantly on the inner surface, the polynucleotide.
- 10 2. The composition of claim 1, wherein said polynucleotide is selected from the group consisting of DNA, RNA, and fragments and analogs thereof.
- 15 3. The composition of claim 1, wherein said polynucleotide is an antisense oligonucleotide.
- 15 4. The composition of claim 1, wherein said cationic lipid is selected from the group consisting of 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxy ethylammonium bromide (DORIE); N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA); 3 β [N-(N',N'-dimethylaminoethane) carbamoly] cholesterol (DC-Chol); and dimethyldioctadecylammonium (DDAB).
- 25 5. The composition of claim 1, wherein said neutral vesicle-forming lipid is a phospholipid.
- 30 6. The composition of claim 1, wherein said liposomes further include a neutral lipid derivatized with a hydrophilic polymer to form a surface coating of hydrophilic polymer chains.
7. The composition of claim 6, wherein said hydrophilic polymer is polyethylene glycol.
8. The composition of claim 1, wherein said liposomes have a size between about 50-

300 nm.

9. The composition of claim 1, wherein said liposomes further include a ligand for targeting to a selected site.

5

10. A liposome composition for *in vivo* administration of a polynucleotide, comprising a suspension of liposomes formed by (i) preparing polynucleotide-cationic lipid particles and (ii) mixing the particles with a neutral vesicle-forming lipid to form liposomes having (i) a bilayer lipid membrane formed of the neutral vesicle-forming lipid and the cationic lipid, (ii) a central core with an inner surface, and (iii) the polynucleotide entrapped in the central core and localized predominantly on the inner surface.

10

11. The composition of claim 10, wherein said polynucleotide is selected from the group consisting of DNA, RNA, and fragments thereof.

15

12. The composition of claim 10, wherein said polynucleotide is an antisense oligonucleotide.

20

13. The composition of claim 10, wherein said liposomes further include a neutral lipid derivatized with a hydrophilic polymer to form a surface coating of hydrophilic polymer chains.

14. The composition of claim 13, wherein said hydrophilic polymer is polyethylene glycol.

25

15. The composition of claim 10, wherein said liposomes have a size between about 50-300 nm.

30

16. The composition of claim 10, wherein said liposomes further include a ligand for targeting to a selected site.

17. A method of entrapping a polynucleotide in liposomes, comprising forming polynucleotide-cationic lipid particles in a lipid solvent suitable for solubilization of the cationic lipid,

adding neutral vesicle-forming lipids to the lipid solvent containing said particles, and evaporating the lipid solvent to form liposomes having the polynucleotide entrapped therein.

5 18. The method of claim 17, wherein said forming further includes the steps of dissolving the polynucleotide in a non-ionic solvent which is immiscible with the lipid solvent,

contacting the polynucleotide with a charge-neutralizing amount of cationic lipid solubilized in the lipid solvent in the presence of a third solvent effective to form a single 10 phase solvent system,

adding additional non-ionic solvent or lipid solvent to the single phase system under conditions effective to form a two-phase system, and

removing the non-ionic solvent phase.

15 19. The method of claim 18, wherein said dissolving includes dissolving the polynucleotide in water, said contacting includes contacting with cationic lipids solubilized in chloroform in the presence of methanol.

20 20. The method of claim 17, wherein said evaporating further includes hydrating with an aqueous medium.


21. A method of administering a polynucleotide to a subject, comprising preparing a suspension of liposomes composed predominantly of liposomes having a bilayer membrane formed of a cationic vesicle-forming lipid and a neutral vesicle-forming 25 lipid, said liposomes having a central core with an inner surface, and entrapped in the core and localized predominantly on the inner surface, the polynucleotides, and administering said liposomes to the subject.

30 22. The method of claim 21, wherein said administering is via intravenous administration.



23. The method of claim 21, wherein said preparing includes preparing a suspension of liposomes including a polynucleotide selected from the group consisting of antisense

oligonucleotides, DNA, RNA, and fragments and analogs thereof.



24. The method of claim 21, wherein said preparing includes preparing liposomes having a surface coating of a hydrophilic polymer by including a neutral lipid derivatized
5 with said hydrophilic polymer.

**Fig. 1**

2/8

**Fig. 2****Fig. 3**

3/8

**Fig. 4A****Fig. 4B**

4/8






Fig. 5


5/8

**Fig. 6A**

6/8

**Fig. 6B**

7/8

**Fig. 6C**

8/8




Fig. 7

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/12937

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/127

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

—

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HARA T ET AL: "Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-labeled cationic liposomes" GENE, vol. 159, no. 2, 4 July 1995, page 167-174 XP004042201 see abstract see page 168, column 1, line 47-49 see pages 168-169, (a) Encapsulation of plasmid pSV2CAT DNA into AF-lps see page 169, column 1, legend of table 1, paragraph "methods" ----- -/-</p>	1, 2, 4, 5, 9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 September 1998

Date of mailing of the international search report

01/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

La Gaetana, R

INTERNATIONAL SEARCH REPORT

Inte onal Application No

PCT/US 98/12937

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 97 04748 A (SCHREIER HANS ;CONARY JON T (US); ADVANCED THERAPIES INC (US)) 13 February 1997 see page 6, line 27 – page 8, line 5 see page 9, line 4-11 see page 12, line 6-10 see page 17, line 10-22 see page 27, line 25-31 see page 30, line 19-21 see page 32, line 3-22 see page 38, line 15-25 see page 46, line 21-26 see page 49, line 13-31 see page 50, line 15-28 see examples 11,14 see claims 1-6,11,12,14</p> <p>---</p>	1-3,8, 10-12, 17,21-24
P,A	<p>FR 2 751 222 A (CAPSULIS) 23 January 1998 see page 4, line 9-19 see page 7, line 1-12 see page 7, line 20-33 see page 12, line 30 – page 13, line 6 see page 14, line 22-25 see claims 1-311,12</p> <p>---</p>	1-3,8, 10-12,17
A	<p>HONG K ET AL: "STABILIZATION OF CATIONIC LIPOSOME-PLASMID DNA COMPLEXES BY POLYAMINES AND POLY(ETHYLENE GLYCOL)-PHOSPHOLIPID CONJUGATES FOR EFFICIENT IN VIVO GENE DELIVERY 2. CONDENSING THE DNA WITH POLYAMINES PRIOR TO THE FORMATION OF LIPOSOME-PLASMID COMPLEXES" FEBS LETTERS, vol. 400, 1997, pages 233-237, XP002067585 see abstract see page 234, column 1, paragraphs 2.2, 2.4</p> <p>---</p>	1,6,7, 10,13,14
A	<p>US 4 394 448 A (SZOKA JR FRANCIS C ET AL) 19 July 1983 see the whole document</p> <p>-----</p>	17-20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/12937

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 21-24 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/12937

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9704748	A 13-02-1997	AU 6691496	A	26-02-1997
FR 2751222	A 23-01-1998	AU 3698297	A	09-02-1998
		WO 9802144	A	22-01-1998
US 4394448	A 19-07-1983	US 4235871	A	25-11-1980
		BE 874408	A	23-08-1979
		DE 2907303	A	06-09-1979
		EP 0004223	A	19-09-1979
		FR 2418023	A	21-09-1979
		GB 2015464	A, B	12-09-1979
		US 4394149	A	19-07-1983